Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-295 in Healthy Japanese Subjects With Overweight or Obesity
NCT07514260Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of GUB014295 in obesity (4 arms), sponsored by AbbVie Inc. Primary endpoint: Number of Participants with Adverse Events. Started Mar 2026; status: active, not recruiting.
02
Drugs
GUB014295
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07514260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514260.